US equities
|
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
NVDA
$239.24
▲+0.14%
MU
$1,045.56
▼-1.73%
SPCX
$171.92
▲+0.49%
AMD
$649.42
▲+2.80%
MRVL
$287.01
▲+5.81%
AVGO
$375.81
▲+3.67%
INTC
$112.50
▼-3.18%
MSFT
$529.30
▲+0.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Seaport Therapeutics, Inc. - Common Stock
(NQ:
SPTX
)
17.37
-1.13 (-6.11%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seaport Therapeutics, Inc. - Common Stock
Seaport Therapeutics to Participate in September Investor Conferences
September 14, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
September 09, 2026
From
PureTech Health plc
Via
Business Wire
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
September 09, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
August 31, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
August 03, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 09, 2026
From
PureTech Health plc
Via
Business Wire
Seaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
June 08, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
June 08, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
Seaport Therapeutics to Participate in Two Upcoming Investor Conferences
June 01, 2026
From
Seaport Therapeutics, Inc.
Via
Business Wire
